PAZ320: Phase I/II data

Interim data from 25 patients aged 18-75 with a BMI of 25-45 kg/m 2 and an HbA1c of <9% in the Phase II portion of an open-label, dose-escalation Phase I/II trial showed that 0.5 g PAZ320 given 2 or 4...